Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Dollar General Corp. (DG) vs Quest Diagnostics Inc (DGX) Price & Performance

Dollar General Corp.Trade
Quest Diagnostics IncTrade

Price performance (Past 24H)

Key statistics

Dollar General Corp. vs Quest Diagnostics Inc — how do they compare? Dollar General Corp. trades at $119.27 (market cap $26.50B), while Quest Diagnostics Inc trades at $205.37 (market cap $22.80B). The key difference: Dollar General Corp. is the larger of the two by market cap, and Dollar General Corp. pays the higher dividend (1.96%). Which is the better fit depends on your goals.

DGDGX
Market Cap
$26.50B$22.80B
Sector
Consumer StaplesHealth
52-Week High
$156.26$216.02
52-Week Low
$95.94$166.42
Enterprise Value
$40.95B$28.82B
Dividend Yield
1.96%1.67%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Dollar General Corp.

Dollar General (DG) trades at $123.44, up 3.8% with strong technical momentum and bullish analyst sentiment. The stock shows consistent earnings beats, with Q1 2026 EPS of $2.00 exceeding expectations of $1.89. Revenue growth continues at $40.61B for 2025, while profit margins face pressure at 3.63%. Recent news highlights the company's back-to-school initiatives and margin expansion efforts.

The outlook remains positive with a $128.45 consensus price target representing 4% upside. Key opportunities include continued same-store sales growth and margin recovery, while risks involve consumer spending sensitivity and competitive pressures in discount retail. The technical setup suggests near-term resistance around $125-$128 levels.

Quest Diagnostics Inc

Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.

DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Dollar General Corp.

A leading American discount retailer, Dollar General operates over 18,000 stores in 47 states, selling branded and private-label products across a wide variety of categories. In fiscal 2021, 77% of net sales came from consumables (including paper and cleaning products, packaged and perishable food, tobacco, and health and beauty items), 12% from seasonal merchandise (such as toys, greeting cards, decorations, and gardening supplies), 7% from home products (for example, kitchen supplies, small appliances, and cookware), and 4% from basic apparel. Stores average roughly 7,400 square feet, and about 75% of Dollar General locations are in towns of 20,000 or fewer people. The firm emphasizes value, with most of its items sold at everyday low prices of $5 or less.

Read more on DG

About Quest Diagnostics Inc

Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.

Read more on DGX